Akili Grabs CE Mark for Children’s Digital ADHD Treatment Post author:Sam Post published:June 22, 2020 Post category:Devices & Diagnostics Letter The FDA last week cleared EndeavorRx for marketing in the U.S. Source: Devices & Diagnostics Letter You Might Also Like Gilead’s Remdesivir Gains Orphan Drug Status as Possible COVID-19 Treatment March 24, 2020 Device Tax Repeal Passes House, Industry Takes Battle to Senate April 7, 2016 Glenmark’s Favipiravir Shows Promise for COVID-19 Patients July 22, 2020
